Estates Gazette quotes Lynsey Inglis on trends in life sciences real estate investment
min readLife Science REIT is set to test investor confidence in the long-term prospects of labs and related real estate after putting itself up for sale, reports Estates Gazette.
The company floated on the London Stock Exchange in November 2021 and has built up a portfolio of assets across the 'Golden Triangle' markets of Oxford, Cambridge and London. But it racked up losses as property values fell and has now launched a strategic review that could see it sold or wound down to return money to shareholders.
Estates Gazette goes on to report that investment in life sciences real estate in the UK peaked during the Covid-19 pandemic in 2022. Additionally, access to venture capital has enabled young life sciences businesses to hire talent, conduct more trials and drive research and development.
Commenting in the article, Lynsey Inglis, Associate in our Real Estate team, explains:
There has certainly been a drop off in life sciences real estate since its peak [...] However, this can be partly explained by the fact we are moving from an investment and development stage to the actual delivery of the space that was in such high demand at the time.
Read the full article in Estates Gazette here (subscription required).
